Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

18:06 EDT 28th May 2016 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 5,900+

Extremely Relevant

Galectin nets $9.2mm through registered direct offering

Galectin Therapeutics Inc. netted $9.2mm through a registered direct offering of 4.76mm common shares at $2.06 (a 17% discount); buyers also received five-year warrants to purchase 3.6mm shares at $2.50. Roth Capital was the placement agent. The company is developing galectin protein-based treatments for fibrotic liver diseases, cancer, and psoriasis.


Enrollment in NASH-FX trial for advanced fibrosis, NASH complete

Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis.The study, which will be led by Stephen A. Harrison, MD, FACP, FAASLD, professor of medicine at the Uniformed Services University of the Health Sciences, San Ant...

Relevant

Galectin completes enrollment for phase 2 trial of GR-MD-02 in fibrosis patients

Galectin Therapeutics has completed enrollment in its phase 2 clinical trial of GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3).


Galectin appoints Dr. Marc Rubin as chairman

Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of […]

Galectin-3 And Cardiac Troponins Reference Values Determined

Galectin-3 is a unique member of chimera type galectins and is involved in a large number of disease processes and...

Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering

NORCROSS, Ga., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,761,900 shares of common stock at a price of $2.06 per share ...

Galectin Therapeutics' (GALT) CEO Peter Traber on Q4 2015 Results - Earnings Call Transcript

BRIEF-Galectin Therapeutics completes enrollment in mid stage trial for NASH drug

* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis

Osteoarthritis: Galectin-1 damages cartilage via inflammation

Galectin-3 inhibition prevents adipose tissue remodelling in obesity

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test

WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD)  today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test for a potential new indication for use as an aid...

As big pharma moves in, biotech Galectin looks to stake claim to NASH market

NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020. 

Galectins in tumour immunity

Dr Gabriel Rabinovich meets with ecancertv at AACR 2016 to discuss galectins. In particular, he has worked with Galectin 1 which, when secreted by tumour cells, kills t cells and promotes non-immunogenic tumourous dendritic cell growth. Beyond immune...

Kesios Therapeutics raises £19 million; names executives

Kesios Therapeutics, a portfolio company of Imperial Innovations Group which is developing novel therapeutics…

BIND Therapeutics collaborates with Affilogic

BIND Therapeutics, a company developing targeted and programmable therapeutics called ACCURINS, has signed…

D. Western Therapeutics Institute, Inc. (4576) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, D. Western Therapeutics Institute, Inc. (4576) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2015-09-11. This 25-page report is available in PDF from $300. Table of Contents Section 1 - About the Company D. Western Therapeutics Institute, Inc. - Key Information D. Western Therapeutics Institute, In...

Placon Therapeutics launches, BTP-114 IND accepted by FDA

Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BTP-114, for which the FDA has accepted an Investigational New Drug (IND) application to begin clinical evaluation in cancer patients. Placon was spun out from Blend Therapeutics (now Tarveda Therapeuti...

Bicycle Therapeutics establishes U.S. operations

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business ...

PTC Therapeutics, MGH ally in R&D of rare disease therapeutics

PTC Therapeutics Inc. and Massachusetts General Hospital are together developing treatments for rare, genetic disorders, including the fatal sensory and autonomic neuropathy known as familial dysautonomia (FD), or Riley-Day syndrome.

Living Therapeutics

An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments

Tarveda spins platinum-based drug assets out into newco Placon Therapeutics

Tarveda Therapeutics Inc. (formerly Blend Therapeutics) spun out its development-stage platinum-based cancer assets into a new independent entity named Placon Therapeutics.

Intensity Therapeutics Inc.

Intensity Therapeutics Inc.'s DfuseRx platform combines known, potent chemotherapeutics with cell-penetration enhancing compounds. The resulting therapeutics are designed to kill tumor cells in masses and then prime the immune system to seek out metastases.

AstraZeneca to collaborate with Moderna Therapeutics to develop mRNA therapeutics

Anglo-Swedish pharma company AstraZeneca will join forces with US biotech firm Moderna Therapeutics to…

#jobs #lifescience PsiOxus Therapeutics: Analytical Development Scientist – Oxfordshire

// Attractive remuneration package: PsiOxus Therapeutics: PsiOxus Therapeutics Ltd is an Oxford based development stage biotechnology company developing novel therapeutics… Oxfordshire from Job Search RSS http://ift.tt/22q9aVt Cet article #jobs #lifescience PsiOxus Therapeutics: Analytical Development Scientist – Oxfordshire est apparu en premier sur Biotech 365.


Quick Search
Advertisement
 

News Quicklinks